US Pharm. 2009;34(3):8. 

Rockville, MD -- In a close decision, the FDA's panel of medical experts recommended that Darvon and Darvocet be pulled from the market based on concerns that the drugs' risks outweigh their benefits. The final decision will ultimately be made by the FDA, but because of the narrow 14-to-12 vote to yank the drugs, it is not clear whether the FDA will actually go through with the final order to take them off pharmacists' shelves. The panel's recommendation was partly the result of a petition from Public Citizen, a public-advocacy organization that challenged the drugs' efficacy versus their risk of causing heart problems.